Johnson & Johnson ( JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to about $143 per share.

Johnson & Johnson’s stock reversed gains made early Wednesday immediately after earnings were released, after the medical technology and drug company beat estimates for the fourth quarter, but offered some mixed guidance.

Procter & Gamble is trading near the top of the Dow Wednesday after the consumer staples giant beat expectations for its fiscal 2025 second quarter.

Corporation reported stronger-than-expected earnings for the third quarter of 2024, with earnings per share (EPS) of $1.04, surpassing the forecast of $0.93. Revenue also exceeded expectations at $3.49 billion compared to the projected $3.

Procter & Gamble topped expectations in fiscal 2025's Q2 with strong revenue figures, but it continues to face challenges with supply chain costs.

Procter & Gamble on Wednesday reported quarterly earnings and revenue that beat analysts' expectations, thanks to growing demand for household staples like toilet paper and laundry products. Shares of the company rose 2.5% in premarket trading.

Key Takeaways Procter & Gamble posted fiscal 2025 second-quarter net sales above analysts' expectations.The company's Baby, Feminine & Family Care segment saw sales rise 3%.Shares of the Tide and Pampers parent rose 3% Wednesday following the results.

The Procter & Gamble Company PG has reported second-quarter fiscal 2025 results, wherein sales and earnings surpassed the Zacks Consensus Estimate and improved year over year. The company’s organic sales grew year over year,